85
77
Growth Score
-2 pts
Heat Score
7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
280429
There is a large unmet medical need for patients suffering from functional Gastro-intestinal disorders.
Peter Milner: CEOPast Role: Espero Biopharma, Director
Pascal Druzgala: Chief Scientific OfficerPast Role: Armetheon, EVP and CSO
About the Company
There is a large unmet medical need for patients suffering from functional Gastro-intestinal disorders. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic drug in the class of 5-HT4 agonists has shown to be effective for a range of these disorders.
